In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Carl Hansen, CEO of AbCellera, for a conversation on the discovery and acceleration of antibody therapeutics.
AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial publ
While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in h
Eli Lilly has started dosing patients in the world's first trial for a medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.
Canadian biotech AbCellera has joined forces with Eli Lilly to co-develop antibody products to prevent and treat COVID-19, the disease caused by the novel SARS-Cov-2 coronavirus.